AOD- 9604

If you are using a screen reader, or having trouble reading this website, please call SculptedMD Direct support at (833) 319-1993.
Medical treatment from licensed providers is provided by the “ SculptedMD Direct Affiliated P.C.s,” an affiliated network of medical Professional Corporations and Associations. To learn more, click here.

*Individual results may vary. 15% body weight loss based on the average weight loss in three 68-week clinical trials of patients on Semaglutide without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity. In a 72-week  (tirzepatide) study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo. In a 72-week Zepbound (tirzepatide) study of adults with diabetes, average weight loss was 12.8% (28 lbs) for 10 mg, 14.7% (33 lbs) for 15 mg, and 3.2% (7 lbs) for placebo. 

In certain situations, where clinically appropriate, a provider may prescribe compounded medication, which is prepared by a state-licensed sterile compounding pharmacy partner. Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality.